AZD4205 is an oral, ATP-competitive, JAK1 selective inhibitor. Nonclinical data showed its higher drug concentration within the gastrointestinal (GI) tract relative to plasma in the rodents, suggesting its potential as an effective and safe treatment option for patients with Crohn’s disease (CD). AZD4205 also has been evaluated in a phase I study in healthy volunteers (HVs). Here we report AZD4205 preclinical data in cells and animal models, and phase I data from HVs.